CELC
Celcuity Inc. Common StockstockNASDAQ
celcuity is a biotech company developing state-of-the-art cell-based assays using our proprietary functional cellular analysis platform. we directly assess the functionality of the disease-related signaling pathways of a patient's diseased cells ex vivo to determine whether a drug therapy has the intended effect on those cells. the patient specific cellular data we provide offers clinicians and pharmaceutical companies unique insight into a patient's response to a drug therapy, and it will change the paradigm of personalized medicine.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 64.17 | 2026-11-12 | -13.36% | 2.487 |
| 1M | 57.12 | 2026-10-19 | -2.66% | 1.509 |
| 3M | 93.65 | 2026-08-19 | -40.63% | 1.609 |
| 6M | 130.96 | 2026-05-19 | -57.54% | 1.306 |
| 1Y | 94.23 | 2025-11-19 | -40.99% | 1.185 |
| 2Y | 12.47 | 2024-11-19 | +345.87% | — |
| 5Y | 16.07 | 2021-11-19 | +245.99% | 0.886 |
Celcuity Inc. Common Stock (NASDAQ:CELC) stock price today is $55.60, and today's volume is 1,011,908. CELC is down 4.154% today. The 30 day average volume is 1.48M. CELC market cap is $2.72B with 48.93M shares outstanding.